Drug intelligence / Profile preview

clomipramine

Development stage
Approved
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Clomipramine is a tricyclic antidepressant (TCA) primarily indicated for the treatment of obsessive-compulsive disorder (OCD) in adults and children aged 10 years and older. It acts mainly as a potent serotonin reuptake inhibitor, increasing serotonin levels in the brain to help maintain mental balance. Clomipramine also inhibits norepinephrine reuptake through its active metabolite, desmethylclomipramine, and exhibits antagonistic activity at several serotonin receptor subtypes. Additional pharmacological effects include alpha-1 adrenergic receptor blockade and sodium channel inhibition, which may contribute to its analgesic properties in neuropathic pain. The drug is available as oral capsules in various strengths[1][4][5][7].

Brand names
Anafranil
Other names
clomipramine hydrochloride
02

Targets

HTR2B (5-Hydroxytryptamine Receptor 2B)HRH1 (Histamine H1 Receptor)HTR2C (5-hydroxytryptamine 2C receptor)mAChR (Muscarinic acetylcholine receptors)NET (Norepinephrine Transporter)ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on clomipramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clomipramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call